Annotation Detail
Information
- Associated Genes
- NRAS
- Associated Variants
-
NRAS MUTATION
NRAS MUTATION - Associated Disease
- cancer
- Source Database
- CIViC Evidence
- Description
- Preclinical study in 16 NRAS mutant cell lines (melanoma, lung carcinoma, neuroblastoma with various Q61, G13, G12 mutations). The combination of metformin and trametinib shown synergistic effects in most tested cell lines (no antagonistic effects observed) and a melanoma xenograft model. Metformin-induced PI3K pathway suppression was identified as a potential mechanism.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1230
- Gene URL
- https://civic.genome.wustl.edu/links/genes/36
- Variant URL
- https://civic.genome.wustl.edu/links/variants/208
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Cancer
- Evidence Direction
- Supports
- Drug
- Trametinib,Metformin
- Evidence Level
- D
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 25504439
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Metformin | Sensitivity | true |
| Trametinib | Sensitivity | true |